Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer, May 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 265 articles:
HTML format


 

Single Articles

  1. DUARTE S, Felicio E, Bernardo G, Gaboleiro F, et al
    Early complications within 30 days after radical cystectomy: The top seven complications and their predictors.
    Investig Clin Urol. 2026;67:254-262.
    PubMed    
    Abstract available

  2. HEO JE, Kim J, Jang WS, Sung HH, et al
    Impact of carcinoma in situ of bladder at transurethral resection and radical cystectomy on survival: Retrospective multicenter study.
    Investig Clin Urol. 2026;67:246-253.
    PubMed    
    Abstract available

  3. CHOI J, Song W, Nam JK, Lim B, et al
    Association of initial transurethral resection staging on survival in radical cystectomy patients.
    Investig Clin Urol. 2026;67:237-245.
    PubMed    
    Abstract available

  4. PENG Z, Huang Z, Nan Z, Yan Y, et al
    A tumor cell membrane-engineered MXene nanoplatform for chemo-photothermal immunotherapy of bladder cancer.
    J Mater Chem B. 2026 Apr 29. doi: 10.1039/d6tb00416.
    PubMed    
    Abstract available

  5. GUBERINA N, Khouya A, Hoffmann C, Fischedick G, et al
    Do AI-based contouring algorithms influence physicians in the online adaptive radiotherapy of patients with bladder cancer?
    Tech Innov Patient Support Radiat Oncol. 2026;38:100401.
    PubMed    
    Abstract available

  6. SAEED AK, Triantafyllakis P, Gordon NS, James ND, et al
    The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.
    Biochem Biophys Rep. 2026;46:102600.
    PubMed    
    Abstract available

  7. HAKOZAKI Y, Sugimoto K, Yamada Y, Danno T, et al
    Proteogenomic detection of tumor-specific somatic mutant proteins in urinary extracellular vesicles for non-invasive monitoring of bladder cancer.
    Front Oncol. 2026;16:1808671.
    PubMed    
    Abstract available

  8. TENG Q, Cheng S, Chen J, Zhu H, et al
    An exploration of GuaLouQuMaiWan related novel prognostic model and search for potential compound pachymic acid in bladder cancer.
    Front Oncol. 2026;16:1714939.
    PubMed    
    Abstract available

  9. LIM S, Standish L, Liu H, Paul E, et al
    Lymph node dissection during cystectomy for non-muscle-invasive bladder cancer: A systematic review.
    BJUI Compass. 2026;7:e70201.
    PubMed    
    Abstract available

  10. ZHU C, Liu M, Liu X, Zhang S, et al
    The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.
    J Nanobiotechnology. 2026 Apr 30. doi: 10.1186/s12951-026-04419.
    PubMed    
    Abstract available

  11. DER B, Varadi M, Nagy N, Kubik A, et al
    Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.
    Cancer Metastasis Rev. 2026;45:26.
    PubMed    
    Abstract available

  12. KANG Y, Zhong G, Lv A, Zhang Y, et al
    Analysis of factors influencing changes in patient-reported quality of life among patients with bladder cancer.
    Eur J Oncol Nurs. 2026;82:103193.
    PubMed    
    Abstract available

  13. GARG T, Lyons T, Rabinowitz K, Gabriel J, et al
    Use of Shared Decision-Making in Non-Muscle-Invasive Bladder Cancer: Protocol for a Scoping Review.
    JMIR Res Protoc. 2026;15:e90101.
    PubMed    
    Abstract available

  14. WANG Y, Yu X
    Development and validation of an interpretable prognostic model for bladder cancer based on lactylation associated genes using SHAP analysis.
    Discov Oncol. 2026 Apr 30. doi: 10.1007/s12672-026-05111.
    PubMed    
    Abstract available

  15. PARK C, Cha HJ, Hong SH, Kim HS, et al
    Combination Therapy with Betulinic Acid and TRAIL Increases ROS-Dependent Cytotoxicity and Inhibits PI3K/Akt Signaling in Human Bladder Cancer Cells.
    Biomol Ther (Seoul). 2026;34:641-651.
    PubMed    
    Abstract available

  16. ZHANG Z, Wang L, An Z, Jiang Y, et al
    Hybrid-Driven Bacillus Calmette-Guerin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer.
    Cyborg Bionic Syst. 2026;7:0492.
    PubMed    
    Abstract available

  17. SINGH G, Kumar A, Kumar L, Mishra N, et al
    Urinary exosomal miRNA profiling reveals sensitive non-invasive detection of bladder cancer.
    BMC Urol. 2026 Apr 29. doi: 10.1186/s12894-026-02130.
    PubMed    


  18. KIM D, Ged Y, Grivas P, Singh P, et al
    Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Apr 1:102557. doi: 10.1016/j.clgc.2026.102557.
    PubMed    
    Abstract available

  19. KANG J, Lee HJ, Oh SB, Nam JK, et al
    Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation.
    Cancer Genomics Proteomics. 2026;23:546-557.
    PubMed    
    Abstract available

  20. OTANI Y, Otani K, Rodden D, Lemieux M, et al
    PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.
    J Natl Compr Canc Netw. 2026;24.
    PubMed    


  21. CHEN H, Yang G, Wei L, Cui Z, et al
    SPI1 inhibits ferroptosis and immune escape of bladder cancer cells by promoting CRYAB expression.
    Pathol Res Pract. 2026;283:156487.
    PubMed    
    Abstract available

  22. CASTELLO DIAS CARNEIRO AP, Batista EC, Gomes Bugano DD, Corradi RG, et al
    Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.
    JCO Glob Oncol. 2026;12:e2500324.
    PubMed    
    Abstract available

  23. CORTES J, Trindade Filho JCS, Rogatto SR
    The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.
    Braz J Med Biol Res. 2026;59:e15526.
    PubMed    
    Abstract available

  24. HIROSE K, Yoshida S, Chen W, Yajima S, et al
    Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2026 Apr 29:hyag072. doi: 10.1093.
    PubMed    
    Abstract available

  25. SHARMA A, Biswal D, Sharma S, Ravani Thrilochana R, et al
    Laparoscopic radical cystectomy in patients with bladder cancer: A modified technique with reduced morbidity - A comparative study.
    Urologia. 2026 Apr 29:3915603261444885. doi: 10.1177/03915603261444885.
    PubMed    
    Abstract available

  26. GOLOMB D, Atamna F, Avda Y, Leonov Polak M, et al
    Tumor site as predictors of pathologic progression in high-grade T1 bladder cancer.
    Urologia. 2026 Apr 29:3915603261444890. doi: 10.1177/03915603261444890.
    PubMed    
    Abstract available

  27. ZHAO Q, Qin Z, Liu R, Zuo K, et al
    Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer.
    Front Bioeng Biotechnol. 2026;14:1773551.
    PubMed    
    Abstract available

  28. MA L, Tao Y, Cheng L, You C, et al
    Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles.
    PeerJ. 2026;14:e21148.
    PubMed    
    Abstract available

  29. ORTIZ-BONILLA CJ, Molony RD, Miyamoto H, Messing E, et al
    Bacillus Calmette-Guerin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer.
    Front Immunol. 2026;17:1707754.
    PubMed    
    Abstract available

  30. LI Y, Wei W, Liu C, Lu H, et al
    A multidimensional nomogram integrating immune, inflammatory, and coagulation markers for personalized prognosis in bladder cancer.
    J Int Med Res. 2026;54:3000605261441388.
    PubMed    
    Abstract available

  31. MOUSAVI SE, Antar RM, Aslani A, Shokri P, et al
    Bladder Cancer Incidence Trends in the United States From 2000 to 2020.
    Cancer Rep (Hoboken). 2026;9:e70548.
    PubMed    
    Abstract available

  32. KRAVCHUK A, Garzaro JRR, Wirtz R, Wolff I, et al
    Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.
    Clin Genitourin Cancer. 2026 Apr 1:102554. doi: 10.1016/j.clgc.2026.102554.
    PubMed    
    Abstract available

  33. FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
    Older Age and Outcomes of Intravesical Bacillus Calmette-Guerin for Non-muscle-invasive Bladder Cancer.
    In Vivo. 2026;40:1585-1594.
    PubMed    
    Abstract available

  34. SACCO E, Bizzarri FP
    Comment on: "Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis".
    Urologia. 2026 Apr 28:3915603261445157. doi: 10.1177/03915603261445157.
    PubMed    


  35. AHANGAR M, Mischak H, Moulavasilis N, Stravodimos K, et al
    Urinary Peptidomic Signatures Predict Overall and Progression-Free Survival in Bladder Cancer.
    Proteomics. 2026 Apr 27:e70135. doi: 10.1002/pmic.70135.
    PubMed    
    Abstract available

  36. HSIEH TH, Kuo HP, Pan CH, Lin YC, et al
    A cyclin D1-CDK4/6-E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer.
    Biol Direct. 2026 Apr 27. doi: 10.1186/s13062-026-00812.
    PubMed    


  37. ZHONG Z, Wu J, Shang H, Tong Y, et al
    Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy.
    J Nanobiotechnology. 2026 Apr 27. doi: 10.1186/s12951-026-04455.
    PubMed    
    Abstract available

  38. CHAMGORDANI PR, Taghiyar S, Abedinzadeh M, Shahanipour K, et al
    Urinary mRNA profiling of autophagy-related genes ATG5, ATG7, MAP1LC3B, and mTOR in non-muscle invasive bladder cancer (NMIBC).
    Cancer Treat Res Commun. 2026;47:101178.
    PubMed    
    Abstract available

  39. HU J, Li B, Xu X, Lin S, et al
    Fusobacterium nucleatum Promotes Bladder Cancer Development Through lncRNA IDH1-AS1-Mediated Autophagy.
    Arch Immunol Ther Exp (Warsz). 2026;74.
    PubMed    
    Abstract available

  40. REN Y, Wu J, Han F
    Predicting Bladder Cancer Prognosis by Integrating Multiple Omics Data through an Adversarial Autoencoder-based Cox proportional hazards Network.
    IEEE Trans Comput Biol Bioinform. 2026;PP.
    PubMed    
    Abstract available

  41. STERNER P, Gimbergsson S, Johansson M, Alamdari F, et al
    Recurrence Rate After Post-Operative Two-Hour Continuous Bladder Irrigation for Primary Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    J Pers Med. 2026;16:175.
    PubMed    
    Abstract available

  42. MEIRELES S, Dias C, Marques A, Silva J, et al
    Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer.
    Curr Issues Mol Biol. 2026;48:345.
    PubMed    
    Abstract available

  43. RESENDE SALGADO L, Zaytoun O, Rabie A, Murphy N, et al
    Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
    Curr Oncol. 2026;33:225.
    PubMed    
    Abstract available

  44. HERRMANN S, Gilfrich C, Siepmann S, Rodas Garzaro JR, et al
    Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.
    Curr Oncol. 2026;33:190.
    PubMed    
    Abstract available

  45. CELLA L, Finocchiaro A, Slusarczyk A, Krajewski W, et al
    Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
    Future Oncol. 2026 Apr 27:1-9. doi: 10.1080/14796694.2026.2661768.
    PubMed    
    Abstract available

  46. SUN M, Hu D, Li T, Chen Z, et al
    Multidimensional transcriptomic analysis and in vitro experiments dissect the landscape of 2',2',4',4'-Tetrabromodiphenyl ether in bladder cancer progression.
    Chem Biol Interact. 2026;434:112079.
    PubMed    
    Abstract available

  47. BELSEY J, Chrosny W, Lapon J
    Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer.
    J Med Econ. 2026;29:1341-1354.
    PubMed    
    Abstract available

  48. SEYYEDSALEHI MS, Hadji M, Rashidian H, Naghibzadeh-Tahami A, et al
    Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.
    Nutr Cancer. 2026 Apr 25:1-12. doi: 10.1080/01635581.2026.2658800.
    PubMed    
    Abstract available

  49. XU L, Pi S, Shen Q, Liu Y, et al
    [Application of whole-process nutritional management based on IKAP theory in patients undergoing radical cystectomy with ileal conduit diversion].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2407-2416.
    PubMed    
    Abstract available

  50. LV J, Yang P, Zheng W, Huang D, et al
    Predicting muscle-invasive bladder cancer with dual-layer detector spectral CT-derived extracellular volume fraction.
    BMC Med Imaging. 2026 Apr 24. doi: 10.1186/s12880-026-02342.
    PubMed    


  51. LLOYD L
    Bladder cancer research is blossoming in Birmingham.
    Nat Rev Urol. 2026 Apr 24. doi: 10.1038/s41585-026-01154.
    PubMed    


  52. SHARIATI S, Mohtadi S, Molavinia S, Salehcheh M, et al
    Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment.
    Sci Rep. 2026 Apr 24. doi: 10.1038/s41598-026-49196.
    PubMed    


  53. RASCIO L, Borghese O, Minelli F, Sica S, et al
    Common femoral artery pseudoaneurysm due to Mycobacterium Bovis infection following intravescical bacillus Calmette-Guerin therapy.
    Indian J Tuberc. 2026;73:277-279.
    PubMed    
    Abstract available

  54. SHIGEHISA R, Fukata S, Pustimbara A, Kawada C, et al
    Discordant fibroblast growth factor receptor 3 (FGFR3) expression between photodynamic diagnosis-positive and -negative bladder cancer lesions: An intra-patient paired analysis.
    Photodiagnosis Photodyn Ther. 2026;59:105488.
    PubMed    
    Abstract available

  55. WU G, Yu W, Yao D, Ma X, et al
    A computational framework identifies a matrisome-related gene signature for bladder cancer prognosis and prioritizes candidate compounds.
    Comput Biol Chem. 2026;124.
    PubMed    
    Abstract available

  56. YIN L, Wang R, Guo FL, Han X, et al
    One-Step Urinary EV Capture-to-SERS on a Temperature-Responsive AuEIH Substrate with Transformer-Based Urologic Cancer Classification.
    Anal Chem. 2026;98:12035-12043.
    PubMed    
    Abstract available

  57. XIE F, Xie C, Yue H, Cui J, et al
    The association of physical activity with urological cancer risk: a systematic review and meta-analysis.
    Nat Commun. 2026;17:3949.
    PubMed    
    Abstract available

  58. LAMMERT SM, Luo W, Zhu AC, Wang P, et al
    PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases.
    Histopathology. 2026;88:1315-1323.
    PubMed    
    Abstract available

  59. FARAG MS, Oghbaei N, Hussain J, Lametti A, et al
    A minor high-grade component in non-invasive papillary urothelial carcinoma is not associated with a more indolent behaviour.
    Histopathology. 2026;88:1430-1442.
    PubMed    
    Abstract available

  60. PICHLER R, van Creij NCH, Mertens LS, Del Giudice F, et al
    FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.
    Eur Urol Oncol. 2026;9:220-226.
    PubMed    
    Abstract available

  61. PAN M, Tao T, Kong D, Gong H, et al
    Aerobic glycolysis in bladder cancer: research advances and targeted therapy potential.
    Front Oncol. 2026;16:1799955.
    PubMed    
    Abstract available

  62. WANG P, Ye F, Wang H, Liu J, et al
    Nano-bionic bacteria armed adoptive macrophage therapy against bladder cancer.
    Mater Today Bio. 2026;38:103130.
    PubMed    
    Abstract available

  63. AGRAWAL S
    A new standard for cisplatin-ineligible muscle-invasive bladder cancer: Landmark results from KEYNOTE-905.
    Indian J Urol. 2026;42:172-173.
    PubMed    


  64. ZHENG Q, Zhao T, Liao E, Cao Z, et al
    PTEN-low associated mismatch repair deficiency and nuclear PD-L1 expression in basal-type bladder cancer.
    Pathol Res Pract. 2026;283:156509.
    PubMed    
    Abstract available

  65. ZHOU Y, Huang Y, Jian N, Zhu Y, et al
    MFAP4 activates PI3K/AKT-NF-kappaB signaling to drive tumor progression and immune evasion in bladder cancer.
    Int Immunopharmacol. 2026;182:116719.
    PubMed    
    Abstract available

  66. DIAZ-FUENTES H, Zapot-Martinez JC, Cabrera-Mora NA, Ramos-Arceo E, et al
    [Solitary fibrous tumor of the prostate mimicking a tumor of the vesicoprostatic junction. Case report].
    Rev Med Inst Mex Seguro Soc. 2026;64:e6779.
    PubMed    
    Abstract available

  67. HUANG T, Xu J, He Y, Shen Y, et al
    Fever and leukemoid reaction in bladder cancer: A case report.
    Oncol Lett. 2026;31:249.
    PubMed    
    Abstract available

  68. NAFI MMI, Md Rahat Hossain K
    DeepBCTPred: deep learning-based prediction of bladder cancer tissues from endoscopic images.
    Bioinform Adv. 2026;6:vbag087.
    PubMed    
    Abstract available

  69. AMARA CS, Piyarathna DWB, Kamal AHM, Chan YS, et al
    Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.
    Cancer Lett. 2026 May 4:218562. doi: 10.1016/j.canlet.2026.218562.
    PubMed    
    Abstract available

  70. HUANG R, Yu J, Bai R, Jiang W, et al
    FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination.
    Cell Death Discov. 2026 May 6. doi: 10.1038/s41420-026-03130.
    PubMed    
    Abstract available

  71. CIMADAMORE A, Lopez-Beltran A, Montironi R, Cheng L, et al
    Molecular Pathology of Genitourinary Tumors: Diagnostic, Prognostic, and Therapeutic Implications.
    Surg Pathol Clin. 2026;19:309-321.
    PubMed    
    Abstract available

  72. WEI Y, Yu Z, Wu S, Li J, et al
    In Vivo Metabolic Engineering of Bladder Cancer-Derived Extracellular Vesicles for Noninvasive Cancer Detection.
    J Am Chem Soc. 2026 May 6. doi: 10.1021/jacs.6c03124.
    PubMed    
    Abstract available

  73. LIANG H, Huang H, Li Y, Lu Y, et al
    Retraction: CircRNA_0058063 functions as a ceRNA in bladder cancer progression via targeting miR-486-3p/FOXP4 axis.
    Biosci Rep. 2026;46:BSR20193484.
    PubMed    


  74. CHENG C, Gao J, Wang R, Wu Y, et al
    NOP2-mediated 5-methylcytosine Regulates Lipid Metabolism Reprogramming to Prime Tumors for Ferroptosis in Bladder Cancer Progression.
    Int J Biol Sci. 2026;22:4399-4416.
    PubMed    
    Abstract available

  75. ZIMAK Z, Vidovic D, Kulis T, Hauptman D, et al
    High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience.
    Front Oncol. 2026;16:1683009.
    PubMed    
    Abstract available

  76. NYKEL A, Kubiak I, Rutkowska L, Kasprzyk Z, et al
    Clinical performance of the urine-based TERT promoter AbsoluteQ Digital PCR for non-invasive detection of bladder cancer.
    Mol Oncol. 2026 May 5. doi: 10.1002/1878-0261.70262.
    PubMed    
    Abstract available

  77. O'CALLAGHAN LA, Powell K, Chess-Williams R, McDermott C, et al
    The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function.
    Pharmacol Res Perspect. 2026;14:e70260.
    PubMed    
    Abstract available


  78. [Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2025 edition)].
    Zhonghua Zhong Liu Za Zhi. 2026;48:462-475.
    PubMed    
    Abstract available

  79. ARTILES MEDINA A, Subiela JD, Muriel Garcia A, Dominguez Gutierrez A, et al
    A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable survival prediction models.
    Urol Oncol. 2026 May 4:S1078-1439(26)00113-4. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available

  80. ZHANG W, Peng X
    Genetic evidence against a causal relationship between myocardial infarction and urological malignancies.
    Can J Urol. 2026;33:387-401.
    PubMed    
    Abstract available

  81. LIATSOS G, Zioutou K, Avramidis K, Vamvakaris K, et al
    Bladder cancer patients hospitalized in a medicine ward including three fuo cases following bacillus calmette-guerin immunotherapy.
    Can J Urol. 2026;33:349-360.
    PubMed    
    Abstract available

  82. LEINUM LR, Jensen BT, Lauridsen SV
    Factors influencing adherence to intravesical instillation therapies for non-muscle-invasive bladder cancer: a scoping review protocol.
    BMJ Open. 2026;16:e116776.
    PubMed    
    Abstract available

  83. SANDIKCI F, Aydin MY, Dogan AE, Yavuz A, et al
    Postoperative ileus as a surgical challenge: comparative outcomes of end-to-end and side-to-side ileal anastomosis in radical cystectomy.
    Ulus Travma Acil Cerrahi Derg. 2026;32:544-551.
    PubMed    
    Abstract available

  84. MITTAL A, Malhotra K, Panwar V, Kishore S, et al
    Targeting Human Epidermal Growth Factor Receptor 2 in Bladder Cancer: Evaluating Its Role as a More Robust Clinicopathological Biomarker Compared to Programmed Death Ligand 1 Expression.
    Urol Res Pract. 2026;52:1-6.
    PubMed    
    Abstract available

  85. WU N, He X
    FTO promotes bladder cancer progression and stemness-associated phenotypes.
    Cytotechnology. 2026;78:103.
    PubMed    
    Abstract available

  86. WANG J, He K, Qi H, Xu J, et al
    Icariside II suppresses bladder cancer progression via endoplasmic reticulum stress-mediated autophagy and lysosomal dysfunction.
    Eur J Pharmacol. 2026;1025:178924.
    PubMed    
    Abstract available

  87. BROWN RJ, Khan MT, Houston AJ, Niu H, et al
    Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guerin vaccine in High-Risk Bladder Cancer.
    J Clin Invest. 2026 Apr 21:e200442. doi: 10.1172/JCI200442.
    PubMed    
    Abstract available

  88. SENER TE, de Oliveira TR, Demirkiran ED, Perri D, et al
    Face and content validation of TURP and TURB simulation models: an EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study.
    World J Urol. 2026;44:339.
    PubMed    
    Abstract available

  89. QIU Z, Xia X, Li X
    Comment on "sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study".
    Support Care Cancer. 2026;34:491.
    PubMed    


  90. CARIGNAN L, Alavi R, Millet M, Lavigne M, et al
    Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.
    Cell Mol Bioeng. 2026;19:207-221.
    PubMed    
    Abstract available

  91. CARIGNAN L, Alavi R, Millet M, Lavigne M, et al
    Erratum: Publisher Correction: Assessing the Relationship Between Bladder Cancer Cell Contractile Phenotypes and Their Invasive Properties.
    Cell Mol Bioeng. 2026;19:223.
    PubMed    
    Abstract available

  92. ISHIZUYA Y, Kawashima A, Yamashita S, Ujike T, et al
    Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer.
    BJUI Compass. 2026;7:e70221.
    PubMed    
    Abstract available

  93. LUO G, Wang W, Tai S, Yan L, et al
    Ribosome biogenesis programs define a three-gene RBscore with prognostic relevance in bladder cancer.
    Front Immunol. 2026;17:1810132.
    PubMed    
    Abstract available

  94. CHENG Y, Deng W, Liu Y, Chen G, et al
    Research progress in augmentation strategies for PD-1/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications.
    Front Immunol. 2026;17:1802404.
    PubMed    
    Abstract available

  95. SHEN J, Wang C, Li T, Guan H, et al
    Identification of a migrasome-related lncRNA signature and its prognostic and immunological role in bladder cancer.
    Front Immunol. 2026;17:1763443.
    PubMed    
    Abstract available

  96. MANTICA G, Esperto F, Malinaric R
    Editorial: Microbial biomarkers predicting BCG therapy response in non-muscle invasive bladder cancer.
    Front Oncol. 2026;16:1831100.
    PubMed    


  97. GREENBERG ZF, Hutchinson T, Kahn J, Graim KS, et al
    Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis.
    J Extracell Biol. 2026;5:e70141.
    PubMed    
    Abstract available

  98. ZHAI Z, Wu F, Sheng G, Jia B, et al
    Identification and Functional Analysis of Targets of Dehydrodiisoeugenol in Bladder Cancer Based on Chemoproteomics-Based Profiling.
    Pharmaceuticals (Basel). 2026;19:651.
    PubMed    
    Abstract available

  99. FALINSKA H, Witkowska-Patena E, Krzyzanowska K, Dziuk M, et al
    Positron Emission Tomography/Computed Tomography in Bladder Cancer: The Role of [(18)F]FDG and Non-FDG Radiotracers.
    Medicina (Kaunas). 2026;62:703.
    PubMed    
    Abstract available

  100. GOLOMB D, Simard S, Eisner A, Avda Y, et al
    The Burden of Worry: Fear of Cancer Recurrence Across Bladder Cancer Survivorship Phases-A Cross-Sectional Analysis.
    J Clin Med. 2026;15:3116.
    PubMed    
    Abstract available

  101. BALTACIOGLU A, Acar O, Sonmez C, Saglican Y, et al
    Serum Trimethylamine-N-Oxide and Its Precursors as a Diagnostic Biomarker Panel for Non-Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2026;27:3591.
    PubMed    
    Abstract available

  102. PACZEK S, Olkowicz M, Kudelski J, Gudowska-Sawczuk M, et al
    The Role of Gasdermin B-Mediated Pyroptosis in Bladder Cancer Diagnosis.
    Int J Mol Sci. 2026;27:3540.
    PubMed    
    Abstract available

  103. KWON WA, Lee YJ, Song YS
    Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:3474.
    PubMed    
    Abstract available

  104. CAO Y, Ma J, Tang X, Cui Y, et al
    HCN2 Promotes BGN Transcription via REST to Regulate Ferroptosis and Tumor Progression in Bladder Cancer.
    Int J Mol Sci. 2026;27:3433.
    PubMed    
    Abstract available

  105. GRAPSA D, Sassi M, Mikou P
    Performance of Urine Fluorescence In Situ Hybridization for Diagnosis of Upper Tract Urothelial Carcinoma: A Comprehensive Review.
    Int J Mol Sci. 2026;27:3406.
    PubMed    
    Abstract available

  106. DURMANOVA V, Mikolaskova I, Javor J, Ocenasova A, et al
    Association of IL6 rs1800795, TNF rs1800629, CCL2 rs1024611 and VEGFA rs699947 Polymorphisms with Bladder Cancer Risk, Tumor Aggressiveness, and HRV Parameters of Autonomic Nervous System Regulation.
    Int J Mol Sci. 2026;27:3361.
    PubMed    
    Abstract available

  107. WU J, Wang Y, Zhao Y, Zheng D, et al
    An unusual cause of a vesical mass: Small bowel diverticulum presenting with a bladder fistula: A case report and review of the literature.
    Medicine (Baltimore). 2026;105:e48536.
    PubMed    
    Abstract available

  108. ZHANG T, Gao Z, Xiao S, Zou X, et al
    Precision Medicine in Bladder Cancer: Redefining Treatment Paradigms Through ADCs, Immunotherapy, and Molecular Subtyping.
    Crit Rev Oncol Hematol. 2026 May 1:105348. doi: 10.1016/j.critrevonc.2026.105348
    PubMed    
    Abstract available

  109. KHATRI C, Das PK, Rattan R, Patowary J, et al
    Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial.
    Sci Rep. 2026 May 2. doi: 10.1038/s41598-026-36231.
    PubMed    
    Abstract available

  110. LIANG Z, Wang L, Li D, Chen Y, et al
    Targeted inhibition of the H3K27ac/OGT/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer.
    Biochim Biophys Acta Mol Basis Dis. 2026 Apr 30:168281.
    PubMed    
    Abstract available

  111. AKIYAMA T, Fukuhara H, Hagiwara Y, Fukata S, et al
    Cost-effectiveness analysis of transurethral resection of bladder tumor with photodynamic diagnosis with 5-aminolevulinic acid hydrochloride for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Apr 30:105495.
    PubMed    
    Abstract available

  112. WU P, Chen L, Yang J, Liang Z, et al
    STEAP2-associated modulation of PI3K/AKT/mTOR signaling contributes to ginkgetin-induced apoptosis in bladder cancer cells.
    Hereditas. 2026 May 1. doi: 10.1186/s41065-026-00686.
    PubMed    
    Abstract available

  113. AGHAYEV A, Durak HM, Hepsen E, Dinc E, et al
    Clinical value of VI-RADS score in predicting repeat transurethral resection in primary bladder cancer: a prospective observational study.
    BMC Urol. 2026 May 1. doi: 10.1186/s12894-026-02131.
    PubMed    
    Abstract available

  114. ZHANG Y, Zhao K, Du W, Hu L, et al
    LC3B promotes bladder cancer cell proliferation via the Sp1-cyclin D1/p27 axis with pan-cancer clinical associations.
    Cell Signal. 2026;145:112560.
    PubMed    
    Abstract available

  115. SHIMODA M, Ito H, Aoki T, Karibe J, et al
    Comparative Analysis of Risk Stratifications for Non-Muscle-Invasive Bladder Cancer According to the Classifications Provided by the National Comprehensive Cancer Network, European Association of Urology, and Japanese Urological Association Guidelines
    Clin Genitourin Cancer. 2026;24:102560.
    PubMed    
    Abstract available

  116. QIN R, Li C, Zhang T, Wang Y, et al
    Identification of naringenin chalcone as a key gut metabolite for bladder cancer intervention: An integrated strategy combining network pharmacology and molecular dynamics simulation.
    Comput Biol Chem. 2026;124.
    PubMed    
    Abstract available

  117. FICHNA K, Crespo-Cuadrado M, Konuparamban A, Di Carlo V, et al
    Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.
    Nano Lett. 2026;26:5618-5627.
    PubMed    
    Abstract available

  118. LI X, Liao L
    Corynebacterium striatum Infection in Incision and Thoracic Cavity with Concurrent CRKP Colonization Following Lung and Bladder Tumor Resection.
    Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag121.
    PubMed    
    Abstract available

  119. GRIFFIN MA, Folk C, Buote NJ
    Laparoscopic stapled partial cystectomy with intraoperative cystourethroscopy for urothelial carcinoma in two dogs.
    Vet Surg. 2026;55:856-863.
    PubMed    
    Abstract available

  120. BENEDETTI B, Foschi N, Pesaresi C, Tartaglione T, et al
    Post-mortem CT detection of fatal air embolism after aerosolized fibrin glue for bladder bleeding.
    J Forensic Sci. 2026;71:1507-1512.
    PubMed    
    Abstract available

  121. ERGIN IE, Sanci A, Hepsen E, Sarikaya K, et al
    Predictive factors for urethral stricture development in patients with bladder tumor: The role of intravesical BCG therapy.
    Actas Urol Esp (Engl Ed). 2026;50:501908.
    PubMed    
    Abstract available

  122. GARG S, Chaurasia JK, Kaushal D, Jayashankar E, et al
    High Immunohistochemical Expression of Runt-Related Transcription Factor 2 (RUNX2) Is Associated With High Tumor Grade, Muscle Invasion, Lymph Node Metastasis, and Advanced Stage in Urinary Bladder Cancer.
    Cureus. 2026;18:e106976.
    PubMed    
    Abstract available

  123. PIZZI JR, Adhikari I, Prakash P, Shi H, et al
    Machine learning-based determination of sex-related bladder cancer biomarkers.
    Front Bioinform. 2026;6:1794098.
    PubMed    
    Abstract available

  124. ZOU XC, Xu LY, Yuan YY, Zhang GY, et al
    Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.
    Front Immunol. 2026;17:1815591.
    PubMed    
    Abstract available

  125. CONROY S, Gagg H, Quayle LA, Adams JA, et al
    Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
    Commun Med (Lond). 2026 May 14. doi: 10.1038/s43856-026-01596.
    PubMed    
    Abstract available

  126. YANG M, Li S, Li R, Dong Y, et al
    Organoid-Based Transcriptomics Indicate IFIT-Associated Immune Modulation during Cryptotanshinone Treatment in Bladder Cancer.
    N Biotechnol. 2026 May 13:S1871-6784(26)00060-9. doi: 10.1016/j.nbt.2026.
    PubMed    
    Abstract available

  127. BROWN JR, Parikh M
    Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2026;24:e267034.
    PubMed    
    Abstract available

  128. LAFITTE E, Sfumato P, Walz J, Billon E, et al
    Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy.
    World J Urol. 2026;44:364.
    PubMed    
    Abstract available

  129. ILTZSCHE M, Wetterling N, Jilek L, Nahhas D, et al
    PSCA-directed nanosized bio-immune conjugates (NANO:BICs) enable selective uptake of TLR9 agonists in bladder cancer cells.
    Front Oncol. 2026;16:1739618.
    PubMed    
    Abstract available

  130. ZHANG D, Li M, Yang B, Yan Z, et al
    Plasmon-Enhanced Magnetic Fluorescent Nanoprobe for Ultrasensitive Detection of Urinary miRNA-96 Enabling Early Diagnosis and Risk Stratification of Bladder Cancer.
    Anal Chem. 2026 May 13. doi: 10.1021/acs.analchem.6c01055.
    PubMed    
    Abstract available

  131. LI Z, Liu C, Wang H
    Exploring the Efficacy of Immunotherapy in Combination with Surgical Resection in High-risk Muscle-invasive Bladder Cancer.
    Iran J Allergy Asthma Immunol. 2026;25:317-329.
    PubMed    
    Abstract available

  132. PATIL B, Hadjiiski L, Sun D, Chan HP, et al
    Bladder cancer segmentation using u-net-based deep-learning.
    Sci Rep. 2026 May 13. doi: 10.1038/s41598-026-52716.
    PubMed    
    Abstract available

  133. COURNEDE M, Gabriel PE, Lottin M, Moschini M, et al
    Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:358.
    PubMed    
    Abstract available

  134. TAN WS, Kamat AM, Lewis R, Porta N, et al
    Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.
    Eur Urol Oncol. 2026 May 13:S2588-9311(26)00127.
    PubMed    
    Abstract available

  135. SHIVANI ZA, Puthalath RT
    Paraganglioma of the urinary bladder with a novel variant of SDHB mutation.
    BMJ Case Rep. 2026;19:e270375.
    PubMed    
    Abstract available

  136. HE Y, Guo H, Wang B, Gao W, et al
    Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.
    Cell Rep Med. 2026 May 12:102795. doi: 10.1016/j.xcrm.2026.102795.
    PubMed    
    Abstract available

  137. YU K, Chen J, Chu YY, Nair S, et al
    A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.
    Cancer Discov. 2026 May 13. doi: 10.1158/2159-8290.CD-26-0099.
    PubMed    
    Abstract available

  138. ALIBEIGINEJAD MH, Esmaielpour A, Tsuboi I, Matsukawa A, et al
    The Prognostic Value of Tumor HER2 Expression in Predicting Oncological Outcomes of Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Int J Mol Sci. 2026;27:4130.
    PubMed    
    Abstract available

  139. TARANTINO G, Citro V, Imbimbo C, Crocetto F, et al
    The Insulin-Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles.
    Int J Mol Sci. 2026;27:3919.
    PubMed    
    Abstract available

  140. KOSTAKOPOULOS N, Evmorfopoulos K, Maresca G, Athanasiadis G, et al
    Combined Robot-Assisted Radical Cystectomy and Robot-Assisted Nephroureterectomy for Synchronous High-Risk Upper Urinary Tract and Bladder Cancer: A Single-Center Retrospective Study and Review of the Literature.
    J Clin Med. 2026;15:3411.
    PubMed    
    Abstract available

  141. HOOPER K, McNall S, Pohl D, Sullivan T, et al
    Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells.
    Cancers (Basel). 2026;18:1401.
    PubMed    
    Abstract available

  142. POPESCU CG, Chipuc S, Zgura D, Haineala B, et al
    Artificial Intelligence-Enhanced Multiparametric MRI and VI-RADS in Bladder Cancer: Current Evidence, Clinical Opportunities and Barriers to Translation.
    Cancers (Basel). 2026;18:1322.
    PubMed    
    Abstract available

  143. ZAURITO P, Scilipoti P, Santangelo A, Birtle A, et al
    Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2026 May 12:S2588-9311(26)00119.
    PubMed    
    Abstract available

  144. CUI A, Liu H, Wang K, Wei S, et al
    Oleic acid modification enables lysosomal escape of phthalocyanine photosensitizer for effective bladder cancer treatment.
    Bioorg Med Chem. 2026;139:118701.
    PubMed    
    Abstract available

  145. HALME ALE, Posa M, Ruotsalainen J, Hallamies S, et al
    International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Apr 17:102563. doi: 10.1016/j.clgc.2026.102563.
    PubMed    
    Abstract available

  146. YANG W, Jin Z, Li Z, Xu W, et al
    O-GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A-TRIM22 Interaction.
    Cancer Sci. 2026 May 11. doi: 10.1111/cas.70416.
    PubMed    
    Abstract available

  147. WANG K, Hu Z, Zhu Y, Piao C, et al
    LASP1 facilitates bladder cancer progression through binding and downregulating MYH9 to inhibit mitochondrial ROS-induced apoptosis.
    Int J Biol Macromol. 2026;366:152483.
    PubMed    
    Abstract available

  148. CHATTERTON K
    Fundamentals of bladder cancer nursing: from diagnosis pathways to holistic care.
    Br J Nurs. 2026;35:S10-S16.
    PubMed    
    Abstract available

  149. JIANG Z, Yuan C, Yuan H, Qin C, et al
    Enhanced detection of bladder cancer using combined circulating tumor cells, urine-derived epithelial cells, and molecular biomarkers.
    J Cancer Res Clin Oncol. 2026 May 10. doi: 10.1007/s00432-026-06469.
    PubMed    
    Abstract available

  150. LOTAN Y, Anai S, Kim H, Gin G, et al
    Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.
    J Transl Med. 2026 May 9. doi: 10.1186/s12967-026-08245.
    PubMed    
    Abstract available

  151. FENG X, Sun D, Xu L, Zhu C, et al
    Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
    Arch Esp Urol. 2026;79:504-512.
    PubMed    
    Abstract available

  152. TURAN T, Efiloglu O, Hamidzada I, Ahmadzada J, et al
    Predictors of BCG Therapy Complications in Non-Muscle-Invasive Bladder Cancer: A Clavien-Dindo-Based Study.
    Arch Esp Urol. 2026;79:495-503.
    PubMed    
    Abstract available

  153. WEI F, Zhao M, Sun X, Ma H, et al
    Genetically Predicted Gut Microbiota and Bladder Cancer Risk: A Mendelian Randomisation Analysis.
    Arch Esp Urol. 2026;79:431-439.
    PubMed    
    Abstract available

  154. NAVARRO-JIMENEZ S, Carrion-Lopez P, Lorenzo-Sanchez MV, Tarraga-Honrubia MA, et al
    Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy.
    Arch Esp Urol. 2026;79:404-414.
    PubMed    
    Abstract available

  155. BAUDET LEON J, Cano Velasco J, Polanco Pujol L, Artero Fullana S, et al
    Current Evidence on the Use of Cystoscopy in the Follow-up of Non-Muscle-Invasive Bladder Cancer: Are We Overusing It? Systematic Review of the Literature.
    Arch Esp Urol. 2026;79:362-370.
    PubMed    
    Abstract available

  156. JEONG J, Jeong G, Kim Y, Ju H, et al
    Machine learning-based integration of transcriptome and digital pathology for predicting chemoresistance in muscle-invasive bladder cancer.
    Exp Mol Med. 2026 May 8. doi: 10.1038/s12276-026-01718.
    PubMed    
    Abstract available

  157. GUERRERO-RAMOS F, Gomez-Canizo C, Rodriguez-Izquierdo M, Hernandez-Arroyo M, et al
    The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.
    Oncologist. 2026 May 8:oyag177. doi: 10.1093.
    PubMed    
    Abstract available

  158. VENTURA Y, Morozov A, Chan R, Combat Faria Tavares M, et al
    Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.
    World J Urol. 2026;44:351.
    PubMed    
    Abstract available

  159. LIU D, Zhang QY
    Virtual Screening of Traditional Chinese Medicine Natural Product Inhibitors Targeting AQP1 for Bladder Cancer.
    Cancer Rep (Hoboken). 2026;9:e70570.
    PubMed    
    Abstract available

  160. WANG J, Liu J, Wang Y, Yan W, et al
    Self-Assembled DNA Nanoladder-Based Electrochemical Biosensor for Rapid and Sensitive Detection of Bladder Tumor-Related miRNA in Urine.
    Anal Chem. 2026;98:13845-13853.
    PubMed    
    Abstract available

  161. NASRALLAH AA, Evans C, Gu L, Parrish JA, et al
    Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.
    Urol Oncol. 2026;44:70-79.
    PubMed    
    Abstract available

  162. GHOREIFI A, Hoimes CJ, Ramalingam S, McManus HD, et al
    Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
    Urol Oncol. 2026;44:80-85.
    PubMed    
    Abstract available

  163. NOEL ODV, Akgul B, Bhandari M, Ramos F, et al
    Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.
    Urol Oncol. 2026;44:176-188.
    PubMed    
    Abstract available

  164. MA M, Li X, Jing M, Yang Z, et al
    Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy.
    Adv Sci (Weinh). 2026;13:e22936.
    PubMed    
    Abstract available

  165. NGUYEN TTA, Osunkoya AO
    Endometriosis Involving the Bladder: A Contemporary Clinicopathologic Analysis of 88 Patients.
    Int J Surg Pathol. 2026;34:866-872.
    PubMed    
    Abstract available

  166. DESHWAL A, Kumar H, Khan A, Parwani A, et al
    Radiation-Induced Epithelioid Angiosarcoma of the Urinary Bladder Mimicking Sarcomatoid Carcinoma: A Rare Entity and Literature Review.
    Int J Surg Pathol. 2026;34:983-989.
    PubMed    
    Abstract available

  167. SHIN Y, Kim S, Rhie SK, An W, et al
    HDAC1 has intrinsic protease activity and regulates transcription through clipping histone H3 N-terminal tail.
    Cell Death Differ. 2026;33:1036-1049.
    PubMed    
    Abstract available

  168. CHENG T, Hao H, Liu C, Li X, et al
    Mapping Patterns of Pelvic Lymph Node Metastasis in Bladder Urothelial Carcinoma: Implications for Personalized Pelvic Radiation Therapy.
    Pract Radiat Oncol. 2026;16:e210-e218.
    PubMed    
    Abstract available

  169. DEHGHANPOUR A, Davenport MS, Muglia VF, Nicola R, et al
    Vesical Imaging Reporting and Data System: Overcoming Barriers to Global Implementation-AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.33634.
    PubMed    
    Abstract available

  170. XU W, Gao J, Wu S, Huang J, et al
    ELN orchestrates prometastatic and immunosuppressive niche in bladder cancer via TGFB1 autocrine signaling.
    JCI Insight. 2026;11:e194700.
    PubMed    
    Abstract available

  171. ALUBAIDY HA, Al-Bdeery AH, Abdul-Adel E, Juda SA, et al
    Role of Cyanidin 3-glucoside Extract in the Induction of Cytotoxicity and Apoptosis in a Rat Bladder Cancer Cell Line.
    Asian Pac J Cancer Prev. 2026;27:1795-1804.
    PubMed    
    Abstract available

  172. ZHAO X, Qin R, Shen C, Hu D, et al
    Integrating machine learning and structural analysis to decipher benzo[a]pyrene-induced bladder cancer networks.
    Discov Oncol. 2026 May 21. doi: 10.1007/s12672-026-05207.
    PubMed    
    Abstract available

  173. ZHAO JG, Chen ZY, Pan HQ, Jin Y, et al
    ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression.
    Cell Death Differ. 2026 May 21. doi: 10.1038/s41418-026-01764.
    PubMed    
    Abstract available

  174. ANGULO-LOZANO JC, Posada-Calderon L, Liu H, Blanchard L, et al
    Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking.
    Urol Oncol. 2026 May 21:S1078-1439(26)00501.
    PubMed    
    Abstract available

  175. DULF DV, Leo A, Coada CA
    Lymphovascular invasion in bladder cancer: from prognostic marker toward a clinical priority.
    Expert Rev Anticancer Ther. 2026 May 21. doi: 10.1080/14737140.2026.2679025.
    PubMed    


  176. SAEED DF, Amer NN, Ismail A, Abdelbary A, et al
    Integrative in silico and clinical validation of urinary lncRNAs (SNHG7 & LINC00675) and beta-catenin mRNA as molecular markers for early bladder cancer detection.
    Clin Transl Oncol. 2026 May 21. doi: 10.1007/s12094-026-04392.
    PubMed    
    Abstract available

  177. BUCKBY A, Gholami M, Hong M, O'Callaghan M, et al
    Androgen Receptor Expression in Urothelial Bladder Cancer-A Systematic Review and Meta-Analysis.
    ANZ J Surg. 2026 May 21. doi: 10.1111/ans.70752.
    PubMed    
    Abstract available


  178. Statement of Retraction: Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-beta signalling pathway.
    Bioengineered. 2026;17:2667619.
    PubMed    


  179. PAVALEAN MI, Madan VL, Pavalean MC, Ceafalan LC, et al
    The role of CD36 in renal and bladder cancer.
    Discoveries (Craiova). 2026;14:e225.
    PubMed    
    Abstract available

  180. LIU X, Bao Y
    Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer.
    Oncol Lett. 2026;32:288.
    PubMed    
    Abstract available

  181. LIU Z, Tan T, Li S, Wang Y, et al
    Bioinformatics analysis and experimental approach identify BRD-family gene DSP as a diagnostic and prognostic indicator in bladder cancer.
    Transl Androl Urol. 2026;15:124.
    PubMed    
    Abstract available

  182. YUAN J, Xing S, Sun W, Zeng S, et al
    Knowledge mapping of photodynamic therapy in bladder cancer: a bibliometric analysis (2000-2025).
    Transl Androl Urol. 2026;15:133.
    PubMed    
    Abstract available

  183. DUQUESNE I, Chakra MA, Myers AA, Boormans JL, et al
    Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay.
    Transl Androl Urol. 2026;15:94.
    PubMed    


  184. XIA Y, Ma B, Huang T, Liu X, et al
    Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.
    Transl Androl Urol. 2026;15:119.
    PubMed    
    Abstract available

  185. ZHOU X, Weng L, Sun T, Jiang Q, et al
    Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.
    Transl Androl Urol. 2026;15:132.
    PubMed    
    Abstract available

  186. CAI S, Ren X, Xia D, Wang M, et al
    MDM4 promotes chemoresistance in bladder cancer by attenuating P53-mediated EMT.
    Transl Androl Urol. 2026;15:112.
    PubMed    
    Abstract available

  187. BRYAN RT, Goel A, Ward DG
    PENK methylation and non-invasive bladder cancer detection.
    Transl Androl Urol. 2026;15:96.
    PubMed    


  188. DELRUE C, Oyaert M, Speeckaert MM
    Urinary PENK DNA methylation for bladder cancer diagnosis: methodological rigor, interpretive boundaries, and the evidence required for clinical translation.
    Transl Androl Urol. 2026;15:97.
    PubMed    


  189. ZHAN W, An D, Lei J, Un H, et al
    Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer patients.
    Transl Androl Urol. 2026;15:110.
    PubMed    
    Abstract available

  190. XIE X, Li Z, Qiu T, Li H, et al
    TRIM26-Mediated CBX6 Ubiquitination Triggers NETosis to Drive Bladder Cancer Tumor Growth via the CNPY2/NF-kappaB Signaling Pathway.
    Drug Dev Res. 2026;87:e70316.
    PubMed    
    Abstract available

  191. CHEN R, Wu D, Wu W, Yang J, et al
    H3K18 lactylation promotes glycolysis in bladder cancer via inhibiting GNG7 through regulating PI3K-AKT signaling pathway.
    World J Surg Oncol. 2026 May 21. doi: 10.1186/s12957-026-04405.
    PubMed    
    Abstract available

  192. LIANG X, Sun Y, Guo Y, Liu B, et al
    Dual-Functional Chitosan-Hyaluronic Acid Dialdehyde Nanoparticles for CD44-Targeted Bcl-2 siRNA Delivery and Photothermal Therapy in Bladder Cancer.
    J Biotechnol. 2026 May 19:S0168-1656(26)00162.
    PubMed    
    Abstract available

  193. DING Y, Jin K, Su X, Zhang L, et al
    Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.
    J Immunother Cancer. 2026;14:e014408.
    PubMed    
    Abstract available

  194. LIU Y, Khetrapal P, Strafford R, Hadjivasilou A, et al
    Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.
    JMIR AI. 2026;5:e68994.
    PubMed    
    Abstract available

  195. SUGAWARA D, Mori N
    Comments on "Enhancing the performance of bp-MRI VI-RADS in detecting muscle-invasive bladder cancer".
    Jpn J Radiol. 2026 May 20. doi: 10.1007/s11604-026-02011.
    PubMed    


  196. ABUDOUBARI S, Tuersun A, Mutailipu S, Chen W, et al
    Interpretable machine learning models for bladder cancer overall survival prediction development and external validation via SEER database and Chinese cohort analysis.
    Discov Oncol. 2026 May 20. doi: 10.1007/s12672-026-05099.
    PubMed    
    Abstract available

  197. LI H, Zhu D
    Development and verification of cell cycle-related gene markers for prognosis in bladder cancer.
    Cancer Biomark. 2026;43:18758592261449024.
    PubMed    
    Abstract available

  198. LI S, Li G, Zhang X
    The Prognostic Nutritional Index Serves as a Novel and Independent Predictor of Recurrence in Patients with Non-Muscle-Invasive Bladder Cancer.
    Nutr Cancer. 2026 May 19:1-10. doi: 10.1080/01635581.2026.2674944.
    PubMed    
    Abstract available

  199. ZHENG Q, Mei H, Weng X, Yang R, et al
    Development and validation of artificial intelligence-based model for bladder cancer immunophenotyping using whole slide images.
    NPJ Precis Oncol. 2026 May 19. doi: 10.1038/s41698-026-01443.
    PubMed    
    Abstract available

  200. SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
    Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
    Oncol Ther. 2026 May 19. doi: 10.1007/s40487-026-00441.
    PubMed    
    Abstract available

  201. LI J, Zhang S, Yu S, Shen Y, et al
    Mechanistic Insights into Xihuang Wan against Bladder Cancer via PI3K/ AKT/BCL2-Mediated Apoptosis Inhibition: Integrated Network Pharmacology, Molecular Docking, Molecular Dynamics Simulations and Experimental Validation.
    Curr Pharm Des. 2026 May 13. doi: 10.2174/0113816128435835260116205839.
    PubMed    
    Abstract available

  202. CHEN J, Zuo J, Zhao J, Zhu X, et al
    From fat to tumor: Exploring the inflammatory bridge via CRP in obesity-related bladder cancer.
    Medicine (Baltimore). 2026;105:e48851.
    PubMed    
    Abstract available

  203. FIGUERAS M, Ingelmo-Torres M, Roldan FL, Goma E, et al
    Role of Bladder EpiCheck((R)) in Bladder cancer: from primary diagnosis to surveillance.
    J Transl Med. 2026 May 18. doi: 10.1186/s12967-026-08249.
    PubMed    
    Abstract available

  204. WANG Y, Nai Z, Zhang J
    LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1.
    World J Surg Oncol. 2026 May 18. doi: 10.1186/s12957-026-04391.
    PubMed    
    Abstract available

  205. WANG B, Zheng X, Hua Q, Zou F, et al
    NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation.
    Cell Oncol (Dordr). 2026 May 18. doi: 10.1007/s13402-026-01219.
    PubMed    
    Abstract available

  206. KAO WH, Liao LZ, Chen YA, Lo UG, et al
    Correction: SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.
    Cell Death Dis. 2026;17:473.
    PubMed    


  207. CHEN R, Su Y, Chen J, Zhu S, et al
    TRIM28-mediated SUMOylation of SREBF1 drives PD?L1 N?glycosylation and immune evasion in bladder cancer.
    Cell Death Dis. 2026 May 18. doi: 10.1038/s41419-026-08798.
    PubMed    
    Abstract available

  208. HANNA J, Fu MZ, Inan B, Guevara D, et al
    Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJUI Compass. 2026;7:e70215.
    PubMed    
    Abstract available

  209. JUAN L, Weiping C
    Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report.
    Clin Case Rep. 2026;14:e72641.
    PubMed    
    Abstract available

  210. COLE A, Shoskes DA, Henderson RJ
    Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.
    Bladder Cancer. 2026;12:23523735261447111.
    PubMed    
    Abstract available

  211. AKAI T, Yamamichi G, Miyamoto H
    Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review.
    Chin Clin Oncol. 2026;15:39.
    PubMed    
    Abstract available

  212. ZENG J, Cao Z, Wang C, Xu Y, et al
    Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer.
    FASEB J. 2026;40:e71904.
    PubMed    
    Abstract available

  213. LAJARA S, Cuda J, Geisler DL, Staniszewski C, et al
    Enhancing urothelial carcinoma diagnosis with artificial intelligence-integrated urine cytology: Biopsy-validated accuracy and efficiency gain.
    Cancer Cytopathol. 2026;134:e70110.
    PubMed    
    Abstract available

  214. ZHANG D, Li X, Xu X, Su M, et al
    METTL3 promotes the progression of bladder cancer through the METTL3/IGF2BP3/MTA1/PI3K/AKT axis.
    Pathol Res Pract. 2026;284:156489.
    PubMed    
    Abstract available

  215. ZHANG X, Shen E, Cheng C, Meng R, et al
    Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report.
    J Cancer Res Clin Oncol. 2026 May 17. doi: 10.1007/s00432-026-06497.
    PubMed    
    Abstract available

  216. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.
    Ann Surg Oncol. 2026 May 17. doi: 10.1245/s10434-026-19790.
    PubMed    
    Abstract available

  217. NADELMANN J, Baca AL, Labagnara K, Dave P, et al
    Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population.
    Clin Genitourin Cancer. 2026;24:102564.
    PubMed    
    Abstract available

  218. LIU K, Chen Z, Jin X, Liang H, et al
    An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.
    Funct Integr Genomics. 2026;26:103.
    PubMed    
    Abstract available

  219. AKAND M, Nakauma-Gonzalez JA, Jatsenko T, Gevaert T, et al
    Transcriptomic profiling across stages of non-muscle-invasive bladder cancer identifies fibroblast activation protein-alpha as a stromal biomarker associated with progression.
    Mol Med. 2026 May 15. doi: 10.1186/s10020-026-01497.
    PubMed    
    Abstract available

  220. FLAIG TW, Spiess PE, Abern M, An Y, et al
    Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
    J Natl Compr Canc Netw. 2026;24:186-203.
    PubMed    
    Abstract available

  221. DAI YN, Tura B, Yu EY, Zeegers MP, et al
    Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programme.
    Clin Nutr. 2026;62:106679.
    PubMed    
    Abstract available

  222. FAHEY C, Sud S, Remella A, Milowsky M, et al
    Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
    Expert Rev Anticancer Ther. 2026 May 15:1-16. doi: 10.1080/14737140.2026.2673109
    PubMed    
    Abstract available

  223. DE SANTIS M, Milloy N, Walley M, Simpson A, et al
    Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.
    Future Oncol. 2026;22:1429-1437.
    PubMed    
    Abstract available

  224. ZIEMBICKI S, Kirkham TL, Arrandale VH, Navaneelan T, et al
    Cancer, chronic obstructive pulmonary disease and ischaemic heart disease in Ontario, Canada workers exposed to diesel engine exhaust.
    Occup Environ Med. 2026;83:78-84.
    PubMed    
    Abstract available

  225. TANG F, Liao S, Hou X
    Infection-driven bladder carcinogenesis: Molecular mechanisms of pathogen-urothelial cell interactions.
    Pathol Res Pract. 2026;283:156488.
    PubMed    
    Abstract available

  226. LASALVIA P, Jaramillo P, Zapata M, Zapata M, et al
    Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.
    Expert Rev Pharmacoecon Outcomes Res. 2026;26:477-488.
    PubMed    
    Abstract available

  227. SUARTZ CV, de Lima RD, Setoue DND, Brito PHS, et al
    Role of Neoadjuvant Therapy in Histological Variant Urothelial Carcinoma.
    Clin Genitourin Cancer. 2026;24:102528.
    PubMed    
    Abstract available

  228. DATA S, Trivedi S, Singh Y, Kumar U, et al
    HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients.
    Ann Surg Oncol. 2026;33:5470-5477.
    PubMed    
    Abstract available

  229. POLVERINO F, Catanzaro C, Nicolazzini M, Petix M, et al
    Alcohol Use Disorder versus Adverse In-Hospital Outcomes after Radical Cystectomy and Ileal Conduit Urinary Diversion.
    Ann Surg Oncol. 2026;33:5847-5853.
    PubMed    
    Abstract available

  230. BOROWCZAK J, Podemska E, Drobnik M, Gawrych A, et al
    HSP90beta as a potential prognostic biomarker in urothelial carcinoma: insights from NF-kappaB, IL-8, and heat-shock protein expression.
    Clin Transl Oncol. 2026;28:2335-2344.
    PubMed    
    Abstract available

  231. HSIEH CC, Tsai LJ, Lee HY, Juan YS, et al
    Arsenic exposure and trend of incidence in urinary cancer from 1979 to 2019: A nationwide population-based study.
    J Formos Med Assoc. 2026;125:507-515.
    PubMed    
    Abstract available

  232. GOTO K, Ando K, Motoi N, Iizuka T, et al
    Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.
    Anticancer Res. 2026;46:2445-2453.
    PubMed    
    Abstract available

  233. FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
    Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2026;46:2599-2608.
    PubMed    
    Abstract available

  234. THI TN, Nguyen VT, Thanh HD, Kwon SY, et al
    Inhibition of AP-1 Reduces CD46-mediated Invasion of Bladder and Colon Cancer Cells.
    Anticancer Res. 2026;46:2525-2539.
    PubMed    
    Abstract available

  235. PACKIAM VT, Black PC, Catto JWF, Ghodoussipour S, et al
    'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.
    BJU Int. 2026 Apr 28. doi: 10.1111/bju.70299.
    PubMed    


  236. CHETHAN GS, Patil NS
    Comment on 'Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 7. doi: 10.1111/bju.70313.
    PubMed    


  237. TILLU N, Wiklund P
    Response to: 'Comment on long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 11. doi: 10.1111/bju.70312.
    PubMed    


  238. CONTIERI R, Martini A, Furrer M, D'Andrea D, et al
    Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
    BJU Int. 2026;137:1058-1066.
    PubMed    
    Abstract available

  239. DIANA P, Di Bello F, Mas L, Gallioli A, et al
    Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.
    BJU Int. 2026;137:1026-1031.
    PubMed    
    Abstract available

  240. LU W, Chen L
    Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.
    Eur Urol. 2026 Apr 23:S0302-2838(26)02098-1. doi: 10.1016/j.eururo.2026.
    PubMed    


  241. ROVIELLO G, Antonuzzo L
    Re: Perioperative enfortumab vedotin and pembrolizumab in bladder cancer.
    Eur Urol. 2026 Apr 30:S0302-2838(26)02145-7. doi: 10.1016/j.eururo.2026.
    PubMed    


  242. BASOURAKOS SP, Shoag J, Calaway A
    Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.
    Eur Urol. 2026 May 13:S0302-2838(26)02149-4. doi: 10.1016/j.eururo.2026.
    PubMed    


  243. HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
    Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press.
    Eur Urol. 2026 May 21:S0302-2838(26)02159-7. doi: 10.1016/j.eururo.2026.
    PubMed    


  244. MOSCHINI M, Scilipoti P, Longoni M, Montorsi F, et al
    Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269.
    Eur Urol. 2026 May 20:S0302-2838(26)02160-3. doi: 10.1016/j.eururo.2026.
    PubMed    


  245. DI BELLO F, Gallioli A, Diana P, Avesani G, et al
    Re: Gallagher et al. RESECT, A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.09.4174.
    Eur Urol. 2026 May 20:S0302-2838(26)02163-9. doi: 10.1016/j.eururo.2026.
    PubMed    


  246. COMPERAT E
    Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2026 May 15:S0302-2838(26)01994-9. doi: 10.1016/j.eururo.2026.
    PubMed    


  247. SUBIELA JD, Gonzalez-Padilla DA, Pichler R, Scilipoti P, et al
    Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient.
    Eur Urol. 2026 May 15:S0302-2838(26)02154-8. doi: 10.1016/j.eururo.2026.
    PubMed    


  248. MANGOLD MH, Baumann G, Wieland VLS, Carl N, et al
    Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled
    Int J Cancer. 2026 Apr 28. doi: 10.1002/ijc.70525.
    PubMed    
    Abstract available

  249. MIYAKE M
    Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
    Int J Urol. 2026;33:e70481.
    PubMed    


  250. LEMES DE, Santos AAS, de Oliveira JL, Roman-Ramos H, et al
    Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression.
    Int J Urol. 2026;33:e70491.
    PubMed    
    Abstract available

  251. KAWAHARA T, Nagumo Y, Tanuma K, Hamada K, et al
    Impact of European Association of Urology Combination and Platinum Eligibility on Real-World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma.
    Int J Urol. 2026;33:e70403.
    PubMed    
    Abstract available

  252. LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
    Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.
    Int J Urol. 2026;33:e70483.
    PubMed    
    Abstract available

  253. MATSUYAMA H
    Reviewer's Comment on Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2026;33:e70499.
    PubMed    


  254. SAKTHIVEL DK, Prabhakar P, Raja Iyub MJ, Garje R, et al
    Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database.
    Int Urol Nephrol. 2026;58:1745-1751.
    PubMed    
    Abstract available

  255. MURTHY V, Maitre P, Pal M, Arora A, et al
    Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2026 May 21:JCO2502093. doi: 10.1200/JCO-25-02093.
    PubMed    
    Abstract available

  256. GHOREIFI A, Lotan Y
    Letter: Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2026 May 1:101097JU0000000000005078. doi: 10.1097/JU.0000000000005078.
    PubMed    


  257. LI EV, Sharma V, Boorjian SA
    Are ctDNA and utDNA the new PSA for Clinically Localized Muscle Invasive Bladder Cancer in the Enfortumab Vedotin/Pembrolizumab Era?
    J Urol. 2026 Apr 29:101097JU0000000000005074. doi: 10.1097/JU.0000000000005074.
    PubMed    


  258. BAHLBURG H, Maas M, Contreras-Sanz A, Othman D, et al
    Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guerin.
    J Urol. 2026 May 20:101097JU0000000000005130. doi: 10.1097/JU.0000000000005130.
    PubMed    
    Abstract available

  259. JOYCE DD, Sharma V, Ratcliff GE, Barocas DA, et al
    Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
    J Urol. 2026 May 18:101097JU0000000000005126. doi: 10.1097/JU.0000000000005126.
    PubMed    
    Abstract available

  260. SCHEPER V, Berninger L, Schwinger M, Woidich R, et al
    Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical Impact.
    Urol Int. 2026 Apr 28:1-10. doi: 10.1159/000552253.
    PubMed    
    Abstract available

  261. SRIDALLA K, Nicolas JD, Zhao L, French DD, et al
    Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.
    Urology. 2026;211:29-34.
    PubMed    
    Abstract available

  262. ZHANG J, Huang L, Wang S, Ding J, et al
    Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy.
    PLoS Biol. 2026;24:e3003786.
    PubMed    
    Abstract available

  263. YANG Z, Ma J, Qiang Z, Xie W, et al
    A new target: AlkBH2 promotes bladder cancer by upregulation of inflammation.
    PLoS One. 2026;21:e0348059.
    PubMed    
    Abstract available

  264. WANG H, Liu H, Sun F, Wu J, et al
    Integrating multi-omics and machine learning to decipher the molecular pathways of bisphenol a-associated lactylation-related genes driving bladder cancer.
    PLoS One. 2026;21:e0347134.
    PubMed    
    Abstract available


  265. Retraction: Does Occupational Exposure to Solvents and Pesticides in Association with Glutathione S-Transferase A1, M1, P1, and T1 Polymorphisms Increase the Risk of Bladder Cancer? The Belgrade Case-Control Study.
    PLoS One. 2026;21:e0349169.
    PubMed    



Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum


;